Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generium And Selexis Debut Dornase Alfa In Russia

Executive Summary

Generium is claiming the launch of the world’s first biosimilar version of Roche’s Pulmozyme after receiving approval for dornase alfa in Russia.

You may also be interested in...



Selexis And Generium Launch Omalizumab Biosimilar In Russia

Selexis and Generium have claimed the launch of an omalizumab biosimilar in Russia, with their Genolar version of Xolair marking the third biosimilar to be launched by the pair following development with Selexis’ SUREtechnology platform.

Russia’s Generium Announces First Biosimilar Of Soliris

Russia’s Generium has announced its launch of the first biosimilar version of Alexion’s blockbuster orphan-disease drug Soliris, one of the most expensive prescription medicines in the world.

Selexis And Turgut Expand Biosimilar Partnership With A Further Two Licensing Agreements

Selexis and Turgut have further expanded their biosimilar development partnership by signing commercial license agreements for two undisclosed biosimilar antibodies. Building on previous deals signed in July 2016 and December 2017, the companies are now working together to develop biosimilars to treat oncology and inflammatory diseases.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB149179

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel